Biocryst Pharmaceuticals Inc Stock Price, News & Analysis

BioCryst Pharmaceuticals (Nasdaq: BCRX) announced the granting of stock options and restricted stock units (RSUs) to 10 newly-hired employees as employment inducements. The compensation committee approved options to purchase 36,700 shares and RSUs covering 89,750 shares of common stock.

The options were granted with an exercise price of $7.95 per share, matching BioCryst's closing price on August 1, 2025. Both options and RSUs will vest over four equal annual installments, starting one year from the grant date, with options having a 10-year term. These grants were made under BioCryst's Inducement Equity Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).

BioCryst Pharmaceuticals (Nasdaq:BCRX) reported outstanding Q2 2025 financial results, marking the company's best quarter historically. ORLADEYO net revenue reached $156.8 million, up 45% year-over-year, with total revenues of $163.4 million. The company achieved an operating profit of $29.8 million (+239% y-o-y) and non-GAAP operating profit of $57.0 million.

Key highlights include record-breaking new patient prescriptions, increased prescriber base, and lower discontinuation rates. BioCryst made a $50 million debt paydown in July and plans to retire all remaining term debt using proceeds from the sale of its European ORLADEYO business. The company maintains its 2025 ORLADEYO revenue guidance of $580-600 million and expects positive cash flows for the full year.

The rare disease pipeline continues advancing with ORLADEYO granules for children (PDUFA date: December 12, 2025) and expected initial data from BCX17725 and avoralstat programs by year-end.

BioCryst Pharmaceuticals (Nasdaq: BCRX) announced a significant leadership transition as CEO Jon Stonehouse plans to retire on December 31, 2025. Charlie Gayer, the company's current Chief Commercial Officer, will assume the role of president on August 1, 2025, and become CEO on January 1, 2026.

Gayer has been instrumental in the successful launch of ORLADEYO®, the company's oral prophylactic therapy for hereditary angioedema, which is expected to achieve peak sales of $1 billion. He also played a key role in the planned sale of BioCryst's European operations. Gayer joined BioCryst in 2015 and brings extensive experience from leadership roles at Talecris Biotherapeutics, Grifols, and GlaxoSmithKline.

BioCryst Pharmaceuticals (Nasdaq: BCRX) has scheduled its second quarter 2025 financial results announcement for Monday, August 4, 2025. The company will host a conference call and webcast at 8:30 a.m. ET to discuss the financial results and provide a corporate update.

Investors can access the live call by dialing 1-844-481-2942 (domestic) or 1-412-317-1866 (international). A live webcast and replay will be available in the investors section at www.biocryst.com.

BioCryst Pharmaceuticals (Nasdaq: BCRX) announced its participation in the 2025 US HAEA National Summit in Baltimore from July 10-13, 2025. The company will present three research posters focusing on HAE treatments, including patient perspectives, treatment burden on pediatric patients under 12 and their caregivers, and attack rates in pediatric patients using prophylactic berotralstat.

CEO Jon Stonehouse emphasized the company's decade-long commitment to the HAE patient community and highlighted BioCryst's achievement in developing the first oral, once-daily prophylactic therapy for HAE in adults and adolescents. Stonehouse will deliver a corporate presentation during the summit.

BioCryst Pharmaceuticals (Nasdaq: BCRX) has appointed Babar Ghias as Chief Financial Officer and Head of Corporate Development. Ghias joins from AvenCell Therapeutics, where he served as CFO since 2022, bringing significant experience in deal-making and operations in rare disease companies.

Throughout his career, Ghias has raised over $1 billion in capital and completed over $80 billion in transactions as an investment banker at Credit Suisse. His previous roles include executive positions at Paragon Biosciences, where he launched four biotechnology companies, and CFO at Marathon Pharmaceuticals, where he led the company's successful sale.

BioCryst Pharmaceuticals (Nasdaq: BCRX) announced the granting of restricted stock units (RSUs) to eight newly-hired employees. The compensation committee approved a total of 57,000 shares of BioCryst common stock as inducement awards on July 1, 2025.

The RSUs will vest over four years in equal annual installments, starting from the one-year anniversary of the grant date, contingent on continued employment. These grants were made under Nasdaq Listing Rule 5635(c)(4) and are subject to BioCryst's Inducement Equity Incentive Plan terms.

BioCryst Pharmaceuticals (Nasdaq: BCRX) has agreed to sell its European ORLADEYO® business to Neopharmed Gentili for up to $264 million, comprising a $250 million upfront payment and up to $14 million in future milestones.

The company plans to use the proceeds to retire its remaining $249 million term debt from Pharmakon, eliminating approximately $70 million in future interest payments. BioCryst expects to end 2027 with approximately $700 million in cash and no term debt, representing a $400 million increase from prior guidance.

The transaction, expected to close by early October, includes the transfer of BioCryst's European organization to Neopharmed Gentili, resulting in projected annual operating expense savings of at least $50 million for BioCryst.

BioCryst Pharmaceuticals presented new data demonstrating the long-term efficacy and safety of ORLADEYO (berotralstat) for hereditary angioedema (HAE) treatment across all age groups at EAACI 2025. Key findings from four studies showed: (1) In pediatric patients, an 86% reduction in attacks requiring professional care was observed after 12 weeks of treatment. (2) The Berolife study showed sustained attack reduction in patients aged >12 years, with median monthly attacks decreasing from 1.0 to 0.44 after six months. (3) Quality of life studies revealed significant improvements in patient outcomes, with 60% achieving Minimal Clinically Important Difference at week 24. (4) Focus group results indicated positive patient experiences, including better disease control and easier treatment management compared to previous therapies. The drug demonstrated consistent safety across all studies, with common side effects including nasopharyngitis and headache.